R
Robert John Steffan
Researcher at Princeton University
Publications - 63
Citations - 2058
Robert John Steffan is an academic researcher from Princeton University. The author has contributed to research in topics: Alkyl & Transplantation. The author has an hindex of 25, co-authored 63 publications receiving 2005 citations.
Papers
More filters
Patent
Silyl ethers of rapamycin
TL;DR: In this article, a method of using rapamycin 42-[O-[(1, 1-dimethylethyl)-dimethylsilyl] ether for the preparation of 31-substituted Rapamycin derivatives was presented.
Journal ArticleDOI
Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity
Christopher C. Chadwick,Susan Chippari,Edward Martin Matelan,Lisa Borges-Marcucci,Amy Eckert,James C. Keith,Leo M. Albert,Yelena Leathurby,Heather A. Harris,Ramesh A. Bhat,Mark A. Ashwell,Eugene John Trybulski,Richard C. Winneker,Steven J. Adelman,Robert John Steffan,Douglas C. Harnish +15 more
TL;DR: This pathway-selective ligand does not promote the classic actions of estrogens such as stimulation of uterine proliferation or ER-mediated gene expression, but is a potent antiinflammatory agent, as demonstrated in the HLA-B27 transgenic rat model of inflammatory bowel disease.
Patent
Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents
TL;DR: A rapamycin derivative is a derivative of Rapamycin of general formula (I) where R1 is alkyl, alkenyl, or alkynyl containing 1 to 6 carbon atoms; or an aromatic moiety selected from the group consisting of phenyl and naphthyl or a heterocyclic moiety selecting from the groups consisting of thiophenyl and quinolinyl or NHCO2 R2 wherein R2 is lower alkyls containing 1-6 carbon atoms or a pharmaceutically acceptable salt thereof.
Patent
Carboxylic acid esters of rapamycin
TL;DR: A compound of structure (I) is defined as a compound of which the substituent is selected from alkyl, aralkyl, fluorenylmethyl, or phenyl which is optionally mono-, di-, or tri-substituted.
Journal ArticleDOI
LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse.
Elaine Quinet,Michael D Basso,Anita R Halpern,David W. Yates,Robert John Steffan,Valerie Clerin,Christine Resmini,James C. Keith,Thomas J. Berrodin,Irene Feingold,Wenyan Zhong,Helen B. Hartman,Mark J. Evans,Stephen J. Gardell,Elizabeth DiBlasio-Smith,William M. Mounts,Edward R. Lavallie,Jay E. Wrobel,Ponnal Nambi,George P. Vlasuk +19 more
TL;DR: Way-252623 (LXR-623) is a highly selective and orally bioavailable synthetic modulator of LXR, which demonstrated efficacy for reducing lesion progression in the murine LDLR−/− atherosclerosis model with no associated increase in hepatic lipogenesis either in this model or Syrian hamsters.